Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

13D Filing: Coliseum Capital and Bioscrip Inc. (BIOS)

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Coliseum Capital Management 0 24,208,030 0 24,208,030 24,208,030 16.5%
Coliseum Capital 8. 18,629,734 0 18,629,734 18,629,734 13.1%
Coliseum Capital Partners 0 15,204,502 0 15,204,502 15,204,502 10.9%
Coliseum Capital Partners II 0 3,425,232 0 3,425,232 3,425,232 2.6%
Adam Gray 0 24,208,030 0 24,208,030 24,208,030 16.5%
Christopher Shackelton 0 24,208,030 0 24,208,030 24,208,030 16.5%
Christopher Shackelton And Adam Gray
Christopher Shackelton And Adam Gray
Coliseum Capital

Page 1 of 10 – SEC Filing

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE
13D/A

Under the Securities Exchange Act of 1934*

(Amendment No. 4)

 

 

BioScrip,
Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

09069N108

(CUSIP Number)

Christopher Shackelton/Adam Gray

105 Rowayton Ave.

Rowayton, CT 06853

(Name,
Address and Telephone Number of Person Authorized to Receive Notices and Communications)

August 17, 2017

(Date of Event Which Requires Filing of this Statement)

 

 

If the filing person has
previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of sections 240.13d-1(e),
240.13d-1(f) or 140.13d-1(g), check the following box.  ☐

The information required on the remainder of
this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all
other provisions of the Act (however, see the Notes).

Follow Bioscrip Inc. (NASDAQ:BIOS)
Trade (NASDAQ:BIOS) Now!

Page 2 of 10 – SEC Filing


CUSIP No. 09069N108 (Common Stock)

  1.

Names of
Reporting Persons.

Coliseum Capital Management, LLC

  2.

Check the Appropriate Box if a Member
of a Group (See Instructions)

(a)  ☐        (b)  ☒

  3.

SEC Use Only

  4.

Source of Funds (See Instructions)

AF

  5.

Check if Disclosure of Legal
Proceedings Is Required Pursuant to Items 2(d) or 2(e)

  6.

Citizenship or Place of
Organization

Delaware

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person

With

  7.

Sole Voting Power

0

  8.

Shared Voting Power

24,208,030 (1)

  9.

Sole Dispositive Power

0

10.

Shared Dispositive Power

24,208,030 (1)

11.

Aggregate Amount Beneficially Owned by Each Reporting Person

24,208,030 (1)

12.

Check if the Aggregate Amount in Row
(11) Excludes Certain Shares (See Instructions)

13.

Percent of Class Represented by
Amount in Row (11)

16.5% (1)

14.

Type of Reporting Person (See
Instructions)

IA

(1) Includes (a) 4,735,932 shares of common stock, $0.0001 par value per share (the Common Shares), (b) 274,854 Common Shares that could be obtained upon conversion of 10,823 shares of Series A Convertible
Preferred Stock, par value $0.0001 per share at a conversion price of $5.17 per share (the Series A Preferred Shares), (c) 15,597,245 Common Shares that could be obtained upon conversion of 614,177 shares of Series C Convertible
Preferred Stock, par value $0.0001 per share at a conversion price of $5.17 per share (the Series C Preferred Shares), (d) 1,800,000 Common Shares that could be obtained upon conversion of 1,800,000 Class A warrants to purchase
Common Shares at a price of $5.17per share (the Class A Warrants), and (e) 1,800,000 Common Shares that could be obtained upon conversion of 1,800,000 Class B warrants to purchase Common Shares at a price of $6.45 per
share (the Class B Warrants and, together with the Class A Warrants, the Warrants).

Page 2 of 10

Follow Bioscrip Inc. (NASDAQ:BIOS)
Trade (NASDAQ:BIOS) Now!

Page 3 of 10 – SEC Filing


CUSIP No. 09069N108 (Common Stock)

  1.

Names of
Reporting Persons.

Coliseum Capital, LLC

  2.

Check the Appropriate Box if a Member
of a Group (See Instructions)

(a)  ☐        (b)  ☒

  3.

SEC Use Only

  4.

Source of Funds (See Instructions)

AF

  5.

Check if Disclosure of Legal
Proceedings Is Required Pursuant to Items 2(d) or 2(e)

  6.

Citizenship or Place of
Organization

Delaware

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person

With

  7.

Sole Voting Power

  8.

Shared Voting Power

18,629,734 (1)

  9.

Sole Dispositive Power

0

10.

Shared Dispositive Power

18,629,734 (1)

11.

Aggregate Amount Beneficially Owned by Each Reporting Person

18,629,734 (1)

12.

Check if the Aggregate Amount in Row
(11) Excludes Certain Shares (See Instructions)

13.

Percent of Class Represented by
Amount in Row (11)

13.1% (1)

14.

Type of Reporting Person (See
Instructions)

OO

(1) Includes (a) 3,628,026 Common Shares, (b) 211,747 Common Shares that could be obtained upon conversion of 8,338 Series A Preferred Shares, (c) 12,016,448 Common Shares that could be obtained upon conversion of 473,175
Series C Preferred Shares, (d) 1,386,757 Common Shares that could be obtained upon conversion of 1,386,757 Class A Warrants, and (e) 1,386,757 Common Shares that could be obtained upon conversion of 1,386,757 Class B Warrants.

Page 3 of 10

Follow Bioscrip Inc. (NASDAQ:BIOS)
Trade (NASDAQ:BIOS) Now!

Page 4 of 10 – SEC Filing


CUSIP No. 09069N108 (Common Stock)

  1.

Names of
Reporting Persons.

Coliseum Capital Partners, L.P.

  2.

Check the Appropriate Box if a Member
of a Group (See Instructions)

(a)  ☐        (b)  ☒

  3.

SEC Use Only

  4.

Source of Funds (See Instructions)

WC

  5.

Check if Disclosure of Legal
Proceedings Is Required Pursuant to Items 2(d) or 2(e)

  6.

Citizenship or Place of
Organization

Delaware

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person

With

  7.

Sole Voting Power

0

  8.

Shared Voting Power

15,204,502 (1)

  9.

Sole Dispositive Power

0

10.

Shared Dispositive Power

15,204,502 (1)

11.

Aggregate Amount Beneficially Owned by Each Reporting Person

15,204,502 (1)

12.

Check if the Aggregate Amount in Row
(11) Excludes Certain Shares (See Instructions)

13.

Percent of Class Represented by
Amount in Row (11)

10.9% (1)

14.

Type of Reporting Person (See
Instructions)

PN

(1) Includes (a) 2,945,866 Common Shares, (b) 173,019 Common Shares that could be obtained upon conversion of 6,813 Series A Preferred Shares, (c) 9,819,242 Common Shares that could be obtained upon conversion of 386,655
Series C Preferred Shares, (d) 1,133,188 Common Shares that could be obtained upon conversion of 1,133,188 Class A Warrants, and (e) 1,133,188 Common Shares that could be obtained upon conversion of 1,133,188 Class B Warrants.

Page 4 of 10

Follow Bioscrip Inc. (NASDAQ:BIOS)
Trade (NASDAQ:BIOS) Now!

Page 5 of 10 – SEC Filing


CUSIP No. 09069N108 (Common Stock)

  1.

Names of
Reporting Persons.

Coliseum Capital Partners II, L.P.

  2.

Check the Appropriate Box if a Member
of a Group (See Instructions)

(a)  ☐        (b)  ☒

  3.

SEC Use Only

  4.

Source of Funds (See Instructions)

WC

  5.

Check if Disclosure of Legal
Proceedings Is Required Pursuant to Items 2(d) or 2(e)

  6.

Citizenship or Place of
Organization

Delaware

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person

With

  7.

Sole Voting Power

0

  8.

Shared Voting Power

3,425,232 (1)

  9.

Sole Dispositive Power

0

10.

Shared Dispositive Power

3,425,232 (1)

11.

Aggregate Amount Beneficially Owned by Each Reporting Person

3,425,232 (1)

12.

Check if the Aggregate Amount in Row
(11) Excludes Certain Shares (See Instructions)

13.

Percent of Class Represented by
Amount in Row (11)

2.6% (1)

14.

Type of Reporting Person (See
Instructions)

PN

(1) Includes (a) 682,160 Common Shares, (b) 38,728 Common Shares that could be obtained upon conversion of 1,525 Series A Preferred Shares, (c) 2,197,206 Common Shares that could be obtained upon conversion of 86,520 Series
C Preferred Shares, (d) 253,569 Common Shares that could be obtained upon conversion of 253,569 Class A Warrants, and (e) 253,569 Common Shares that could be obtained upon conversion of 253,569 Class B Warrants.

Page 5 of 10

Follow Bioscrip Inc. (NASDAQ:BIOS)
Trade (NASDAQ:BIOS) Now!

Page 6 of 10 – SEC Filing


CUSIP No. 09069N108 (Common Stock)

  1.

Names of
Reporting Persons.

Adam Gray

  2.

Check the Appropriate Box if a Member
of a Group (See Instructions)

(a)  ☐        (b)  ☒

  3.

SEC Use Only

  4.

Source of Funds (See Instructions)

AF

  5.

Check if Disclosure of Legal
Proceedings Is Required Pursuant to Items 2(d) or 2(e)

  6.

Citizenship or Place of
Organization

United States

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person

With

  7.

Sole Voting Power

0

  8.

Shared Voting Power

24,208,030 (1)

  9.

Sole Dispositive Power

0

10.

Shared Dispositive Power

24,208,030 (1)

11.

Aggregate Amount Beneficially Owned by Each Reporting Person

24,208,030 (1)

12.

Check if the Aggregate Amount in Row
(11) Excludes Certain Shares (See Instructions)

13.

Percent of Class Represented by
Amount in Row (11)

16.5% (1)

14.

Type of Reporting Person (See
Instructions)

IN

(1) Includes (a) 4,735,932 Common Shares, (b) 274,854 Common Shares that could be obtained upon conversion of 10,823 shares of Series A Convertible Preferred Stock, (c) 15,597,245 Common Shares that could be obtained
upon conversion of 614,177 shares of Series C Convertible Preferred Stock, (d) 1,800,000 Common Shares that could be obtained upon conversion of 1,800,000 Class A Warrants, and (e) 1,800,000 Common Shares that could be obtained upon conversion
of 1,800,000 Class B Warrants.

Page 6 of 10

Follow Bioscrip Inc. (NASDAQ:BIOS)
Trade (NASDAQ:BIOS) Now!

Page 7 of 10 – SEC Filing


CUSIP No. 09069N108 (Common Stock)

  1.

Names of
Reporting Persons.

Christopher Shackelton

  2.

Check the Appropriate Box if a Member
of a Group (See Instructions)

(a)  ☐        (b)  ☒

  3.

SEC Use Only

  4.

Source of Funds (See Instructions)

AF

  5.

Check if Disclosure of Legal
Proceedings Is Required Pursuant to Items 2(d) or 2(e)

  6.

Citizenship or Place of
Organization

United States

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person

With

  7.

Sole Voting Power

0

  8.

Shared Voting Power

24,208,030 (1)

  9.

Sole Dispositive Power

0

10.

Shared Dispositive Power

24,208,030 (1)

11.

Aggregate Amount Beneficially Owned by Each Reporting Person

24,208,030 (1)

12.

Check if the Aggregate Amount in Row
(11) Excludes Certain Shares (See Instructions)

13.

Percent of Class Represented by
Amount in Row (11)

16.5% (1)

14.

Type of Reporting Person (See
Instructions)

IN

(1) Includes (a) 4,735,932 Common Shares, (b) 274,854 Common Shares that could be obtained upon conversion of 10,823 shares of Series A Convertible Preferred Stock, (c) 15,597,245 Common Shares that could be obtained
upon conversion of 614,177 shares of Series C Convertible Preferred Stock, (d) 1,800,000 Common Shares that could be obtained upon conversion of 1,800,000 Class A Warrants, and (e) 1,800,000 Common Shares that could be obtained upon conversion
of 1,800,000 Class B Warrants.

Page 7 of 10

Follow Bioscrip Inc. (NASDAQ:BIOS)
Trade (NASDAQ:BIOS) Now!

Page 8 of 10 – SEC Filing


CUSIP No. 09069N108 (Common Stock)

Explanatory Note: This Amendment No. 4 (this Amendment) to the Schedule 13D relating
to BioScrip, Inc., a Delaware corporation (the Issuer), filed by the Filers (as defined below) with the U.S. Securities and Exchange Commission (the Commission) on March 19, 2015 (the Initial 13D), as amended
and supplemented by Amendment No. 1 to the Initial 13D filed on August 27, 2015, Amendment No. 2 to the Initial 13D filed on April 5, 2016, and Amendment No. 3 to the Initial 13D filed on June 22, 2016, amends and
supplements certain of the items set forth therein.

As used in this Amendment, the term Filers collectively refers to:

Coliseum Capital Management, LLC, a Delaware limited liability company (CCM);
Coliseum Capital, LLC, a Delaware limited liability company (CC);
Coliseum Capital Partners, L.P., a Delaware limited partnership (CCP);
Coliseum Capital Partners II, L.P., a Delaware limited partnership (CCP2);
Adam Gray (Gray); and
Christopher Shackelton, a director of the Issuer (Shackelton).

Item 5. Interest in
Securities of the Issuer.

Item 5 is amended and supplemented as follows:

The information relating to the beneficial ownership of shares of common stock, $0.0001 par value per share (the Common Shares) of BioScrip, Inc.
(the Issuer) by each of the Filers set forth in Rows 7 through 13 of the cover pages hereto is incorporated herein by reference. The percentages set forth in Row 13 for all cover pages filed herewith are calculated based upon
127,475,226 Common Shares outstanding as of August 7, 2017, as reported in the Issuers Form 10-Q for the quarterly period ended June 30, 2017, filed with the Commission on August 8, 2017.

The Filers effected the following transactions in the Common Shares in open market transactions on the dates indicated, and such transactions are the
only transactions in the Common Shares by the Filers in the sixty days preceding the filing of this Amendment.


Name

Purchase
or Sale
Date Number
of Shares
Weighted
Average
Price Per
Share

CCP

Sale 08/15/17 134,889 $ 3.15

CCP2

Sale 08/15/17 32,082 $ 3.15

Separate Account

Sale 08/15/17 49,329 $ 3.15

CCP

Sale 08/16/17 72,184 $ 3.11

CCP2

Sale 08/16/17 17,155 $ 3.11

Separate Account

Sale 08/16/17 26,363 $ 3.11

CCP

Sale 08/17/17 345,751 $ 3.05

CCP2

Sale 08/17/17 82,169 $ 3.05

Separate Account

Sale 08/17/17 126,556 $ 3.05

Except as set forth in Item 6 hereof, no other person has the right to receive or the power to direct the receipt of dividends
from, or the proceeds from the sale of, the Common Shares, the Series A Convertible Preferred Stock, par value $0.0001 per share (the Series A Preferred Shares), the Series C Convertible Preferred Stock, par value $0.0001 per share (the
Series C Preferred Shares and, together with the Series A Preferred Shares, the Preferred Shares) the Class A warrants to purchase Common Shares at a price of $5.17 per share (the Class A Warrants) or
the Class B warrants to purchase Common Shares at a price of $6.45 per share (the Class B Warrants and , together with the Class A Warrants, the Warrants) reported herein.

Page 8 of 10

Follow Bioscrip Inc. (NASDAQ:BIOS)
Trade (NASDAQ:BIOS) Now!

Page 9 of 10 – SEC Filing


CUSIP No. 09069N108 (Common Stock)

The information in Item 6 is incorporated herein by reference.

Item 6. Contracts, Arrangement, Understandings or Relationships with Respect to Securities of the Issuer.

CCM is an investment adviser whose clients, including CCP, CCP2 and the Separate Account, have the right to receive or the power to direct the receipt of
dividends from, or the proceeds from the sale of, the Common Shares, the Preferred Shares and the Warrants. CC is the general partner of CCP and CCP2. Gray and Shackelton are the managers of CC and CCM. CCM may have the right to receive
performance-related fees from the Separate Account and CC may have the right to receive performance-related fees from CCP and CCP2.

Page 9 of 10

Follow Bioscrip Inc. (NASDAQ:BIOS)
Trade (NASDAQ:BIOS) Now!

Page 10 of 10 – SEC Filing


CUSIP No. 09069N108 (Common Stock)

SIGNATURES

After reasonable inquiry and to the best of my knowledge, I certify that the information set forth in this statement is true, complete and correct.

Dated: August 18, 2017

COLISEUM CAPITAL MANAGEMENT, LLC COLISEUM CAPITAL, LLC
By:

/s/ Thomas Sparta

Thomas Sparta, Attorney-in-fact

By:

/s/ Thomas Sparta

Thomas Sparta, Attorney-in-fact

COLISEUM CAPITAL PARTNERS, L.P.
COLISEUM CAPITAL PARTNERS II, L.P.
By: Coliseum Capital, LLC, General Partner By: Coliseum Capital, LLC, General Partner
By:

/s/ Thomas Sparta

Thomas Sparta, Attorney-in-fact

By:

/s/ Thomas Sparta

Thomas Sparta, Attorney-in-fact

CHRISTOPHER SHACKELTON ADAM GRAY
By:

/s/ Thomas Sparta

Thomas Sparta, Attorney-in-fact

By:

/s/ Thomas Sparta

Thomas Sparta, Attorney-in-fact

Page 10 of 10

Follow Bioscrip Inc. (NASDAQ:BIOS)
Trade (NASDAQ:BIOS) Now!